Using Enhanced Imaging to Evaluate Tumor Margins for Canine Mammary Cancer and Soft Tissue Sarcoma

Breed(s): Pembroke Welsh Corgi, American Eskimo Dog, Irish Setter, Briard, Glen of Imaal Terrier, Afghan Hound, Siberian Husky, German Shorthaired Pointer, Shih Tzu, Norwich Terrier, Great Pyrenees, Skye Terrier, Canaan Dog, Cardigan Welsh Corgi, Golden Retriever, Bernese Mountain Dog, Rottweiler, Welsh Terrier, Flat-Coated Retriever, Saluki, French Bulldog, Field Spaniel, Boykin Spaniel, Boston Terrier, Scottish Terrier, Tibetan Terrier, Kerry Blue Terrier, Australian Terrier, Bearded Collie, Tibetan Spaniel, Kuvasz, Bedlington Terrier, Beauceron, Standard Schnauzer
Study Type: Clinical Study
Study Location: University of Illinois, Urbana-Champaign

Surgery is the primary treatment for many common tumors affecting dogs including mammary tumors and soft tissue sarcomas. For these tumors, the best chance of cure is offered if the surgeon can fully remove both visible and microscopic traces of the tumor. Unfortunately, to do this, surgeons must rely on indirect and crude methods to assess the extent of the tumor during surgery. The success of the procedure will not be known until several days later, following sample assessment by the pathologist. After surgery, decisions regarding the necessity of further treatment and ultimately the prognosis for the patient are often based off the histopathology results. For malignant tumors, if the disease is minimally or incompletely removed, further surgery or radiation therapy is often required. Additional treatments such as these can result in further risk and discomfort for the dog as well as be an emotional and financial cost for owners. Optical coherence tomography is an emerging diagnostic imaging tool that uses light waves to generate real-time, high-resolution images of tissue at a microscopic level. These images can be used to evaluate for residual disease at the time of surgery giving immediate feedback to the surgeon.

This study is testing optical coherence tomography for detection of residual cancer following surgical removal of canine mammary tumors and soft tissue sarcomas. Dogs enrolled in the study will have imaging at the time of surgery and the tumor will be imaged following removal. In the future this technology could be used to assess for residual cancer in surgery to benefit patients by guiding accurate treatment recommendations and attempting to reduce the need for other additional treatments.

Related Grant: 02204: Using Enhanced Imaging to Evaluate Tumor Margins for Canine Mammary Cancer and Soft Tissue Sarcoma

More Information


Contact Information:
Name: Laura Selmic or Rebecca Kamerer
Email: or
Phone: 217-333-5300

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Make an Investment Today:

  • $50
  • $100
  • $250
  • $1000
  • Give Now
Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2018 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software